Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer
November 07 2019 - 7:00AM
Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced the appointment of Luisa Stamm, MD,
PhD, as Chief Medical Officer. Dr. Stamm is an infectious disease
specialist whose industry career has focused on the development of
therapeutics for hepatitis C virus (HCV) and HIV.
“We are excited to have Luisa joining the Assembly team. Her
clinical training, research experience, and track record in drug
development make her ideally suited to lead clinical activities
across our HBV and microbiome programs,” said John McHutchison, AO,
MD, Chief Executive Officer and President. “Luisa has in the past
repeatedly demonstrated her ability to execute both effectively and
efficiently on clinical development strategy from early trials
through to registrational studies, including regulatory filings.
Her expertise and leadership will be particularly important as we
advance our core inhibitors into later stage development for the
treatment of HBV.”
“I am excited to join Assembly’s leadership team and to help the
company pursue potentially curable, finite treatments for the 250
million patients worldwide living with chronic HBV infection,” said
Dr. Stamm. “I’m encouraged by the potential for core inhibitors to
be a cornerstone of transformative therapeutic regimens and by the
data we have shown to date with our portfolio candidates. I also
look forward to advancing and expanding our pipeline of microbiome
candidates from our differentiated platform for oral live
biotherapeutics.”
Dr. Stamm joins Assembly from Gilead where she was a senior
member of the HCV and HIV clinical research teams with
responsibility for scientific and clinical development activities
and overall research strategy. She was Executive Director in the
Liver Diseases Therapeutic Area, serving as project team leader of
the development of two HCV therapeutics which are now marketed
(VOSEVI® and EPCLUSA®1), and Executive Director in the HIV and
Emerging Viruses Therapeutic Area, focusing on the development of
broadly neutralizing antibodies for HIV cure. In these roles, she
supervised Phase 1, 2 and 3 clinical trials, and the filing of
initial marketing applications in US, EU, Canada, China and Japan.
Previously she was a Clinical Fellow and Instructor of Medicine at
Harvard Medical School and Assistant in Medicine at Massachusetts
General Hospital where she completed a clinical fellowship in
infectious diseases and a post-doctoral research fellowship in
bacterial pathogenesis. She is widely published in the areas of
viral disease and microbial pathogenesis. Dr. Stamm received an MD
and PhD in Biomedical Sciences from the University of California,
San Francisco, and a BA in Biochemical Sciences from Harvard
College.
About Assembly Biosciences Assembly
Biosciences, Inc. is a clinical-stage biotechnology company
developing innovative therapeutics targeting hepatitis B virus
(HBV) and diseases associated with the microbiome. The HBV program
is focused on advancing a new class of potent, oral core inhibitors
that have the potential to increase cure rates for chronically
infected patients. The microbiome program is developing novel oral
live microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP banking and production, and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information, visit
assemblybio.com.
Forward-Looking Statements The information in
this press release contains forward-looking statements regarding
future events, including statements about the clinical and
therapeutic potential of core inhibitors and advancement of our
core inhibitors into later stage clinical trials. Certain
forward-looking statements may be identified by reference to a
future period or by use of forward-looking terminology such as
“advances” and “potential.” Assembly intends such forward-looking
statements to be covered by the safe harbor provisions contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. More information
about the risks and uncertainties faced by Assembly are more fully
detailed under the heading “Risk Factors” in Assembly's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2019 filed with
the Securities and Exchange Commission. Except as required by law,
Assembly assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts Assembly Biosciences, Inc. Investors:
Lauren Glaser (415) 521-3828 lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2024 to May 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From May 2023 to May 2024